

**Clinical Policy: Icosapent Ethyl (Vascepa)**

Reference Number: CP.PMN.187

Effective Date: 03.01.19

Last Review Date: 02.22

Line of Business: Commercial, HIM, Medicaid

[Revision Log](#)

See [Important Reminder](#) at the end of this policy for important regulatory and legal information.

**Description**

Icosapent ethyl (Vascepa<sup>®</sup>) is an ethyl ester of eicosapentaenoic acid (EPA).

**FDA Approved Indication(s)**

Vascepa is indicated:

- As adjunct to maximally tolerated statin therapy to reduce the risk of myocardial infarction, stroke, coronary revascularization, and unstable angina requiring hospitalization in adult patients with elevated triglyceride (TG) levels ( $\geq 150$  mg/dL) and:
  - Established cardiovascular disease (CVD) or
  - Diabetes mellitus and 2 or more additional risk factors for cardiovascular disease
- As an adjunct to diet to reduce TG levels in adult patients with severe ( $\geq 500$  mg/dL) hypertriglyceridemia

Limitation(s) of use: The effect of Vascepa on the risk for pancreatitis in patients with severe hypertriglyceridemia has not been determined.

**Policy/Criteria**

*Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.*

It is the policy of health plans affiliated with Centene Corporation<sup>®</sup> that Vascepa is **medically necessary** when the following criteria are met:

**I. Initial Approval Criteria****A. Hypertriglyceridemia without ASCVD (must meet all):**

1. Diagnosis of hypertriglyceridemia;
2. Age  $\geq 18$  years;
3. Fasting TG  $\geq 500$  mg/dL (lab must be dated within 90 days);
4. Failure of a  $\geq 3$  consecutive month trial of fibrates therapy in the last 6 months at up to maximally indicated doses, unless contraindicated or clinically significant adverse effects are experienced;
5. Failure of omega-3-acid ethyl esters (generic Lovaza<sup>®</sup>) at up to maximally indicated doses, unless contraindicated or clinically significant adverse effects are experienced;
6. If request is for brand Vascepa, member must use generic icosapent ethyl, unless contraindicated or clinically significant adverse effects are experienced;
7. Dose does not exceed 4 g (4 capsules) per day.

**Approval duration: 6 months**

**B. Reduction of Cardiovascular Disease Risk** (must meet all):

1. Diagnosis of one of the following (a or b):
  - a. Atherosclerotic cardiovascular disease (ASCVD) as evidenced by a history of any one of the following conditions (i-vii):
    - i. Acute coronary syndromes;
    - ii. Clinically significant coronary heart disease (CHD) diagnosed by invasive or noninvasive testing (such as coronary angiography, stress test using treadmill, stress echocardiography, or nuclear imaging);
    - iii. Coronary or other arterial revascularization;
    - iv. Myocardial infarction;
    - v. Peripheral arterial disease presumed to be of atherosclerotic origin;
    - vi. Stable or unstable angina;
    - vii. Stroke or transient ischemic attack (TIA);
  - b. Diabetes with  $\geq 2$  CVD risk factors (*see Appendix G*);
2. Age  $\geq 45$  years;
3. Documentation of both of the following (labs must be dated within 90 days) (a and b):
  - a. Fasting TG between 150-499 mg/dL;
  - b. Low-density lipoprotein cholesterol (LDL-C) between 41-100 mg/dL;
4. For members on statin therapy, both of the following (a and b):
  - a. Vascepa is prescribed in conjunction with a statin at the maximally tolerated dose;
  - b. Member has been adherent for at least the last 4 months to maximally tolerated doses of one of the following statin regimens (i, ii, or iii):
    - i. A high intensity statin (*see Appendix D*);
    - ii. A moderate intensity statin (*see Appendix D*), and member has one of the following (a or b):
      - a) Intolerance to two high intensity statins;
      - b) A statin risk factor (*see Appendix E*);
    - iii. A low intensity statin, and member has one of the following (a or b):
      - a) Intolerance to one high and one moderate intensity statins;
      - b) A statin risk factor (*see Appendix E*) and history of intolerance to two moderate intensity statins;
5. For members not on statin therapy, member meets one of the following (a or b):
  - a. Statin therapy is contraindicated per Appendix F;
  - b. For members who are statin intolerant, member has tried at least two statins, one of which must be hydrophilic (pravastatin, fluvastatin, or rosuvastatin), and member meets one of the following (i or ii):
    - i. Member has documented statin risk factors (*see Appendix E*);
    - ii. Member is statin intolerant due to statin-associated muscle symptoms (SAMS) and meets both of the following (a and b):
      - a) Documentation of intolerable SAMS persisting at least two weeks, which disappeared with discontinuing the statin therapy and recurred with a statin re-challenge;
      - b) Documentation of re-challenge with titration from lowest possible dose and/or intermittent dosing frequency (e.g., 1 to 3 times weekly);

6. If request is for brand Vascepa, member must use generic icosapent ethyl, unless contraindicated or clinically significant adverse effects are experienced;
7. Dose does not exceed 4 g (4 capsules) per day.

**Approval duration: 6 months**

**C. Other diagnoses/indications**

1. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace, and CP.PMN.53 for Medicaid.

**II. Continued Therapy**

**A. Hypertriglyceridemia without ASCVD (must meet all):**

1. Currently receiving medication via Centene benefit or member has previously met initial approval criteria;
2. Member is responding positively to therapy as evidenced by one of the following (a or b):
  - a. Initial re-authorization: 20% reduction in TG levels from baseline;
  - b. Subsequent re-authorizations: continued reduction or maintenance in reduction of TG levels from baseline;
3. If request is for brand Vascepa, member must use generic icosapent ethyl, unless contraindicated or clinically significant adverse effects are experienced;
4. If request is for a dose increase, new dose does not exceed 4 g (4 capsules) per day.

**Approval duration: 12 months**

**B. Reduction of Cardiovascular Disease Risk (must meet all):**

1. Currently receiving medication via Centene benefit or member has previously met initial approval criteria;
2. Member is responding positively to therapy as evidenced by no increase in TG and LDL-C levels from baseline;
3. If statin tolerant, documentation of adherence to a statin at the maximally tolerated dose;
4. If request is for brand Vascepa, member must use generic icosapent ethyl, unless contraindicated or clinically significant adverse effects are experienced;
5. If request is for a dose increase, new dose does not exceed 4 g (4 capsules) per day.

**Approval duration: 12 months**

**C. Other diagnoses/indications (must meet 1 or 2):**

1. Currently receiving medication via Centene benefit and documentation supports positive response to therapy.  
**Approval duration: Duration of request or 12 months (whichever is less);** or
2. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace, and CP.PMN.53 for Medicaid.

**III. Diagnoses/Indications for which coverage is NOT authorized:**

- A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policies – CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace, and CP.PMN.53 for Medicaid, or evidence of coverage documents.

**IV. Appendices/General Information**

*Appendix A: Abbreviation Key*

ASCVD: atherosclerotic cardiovascular disease	FDA: Food and Drug Administration
CVD: cardiovascular disease	LDL-C: low-density lipoprotein cholesterol
EPA: eicosapentaenoic acid	SAMS: statin-associated muscle symptoms
	TG: triglyceride

*Appendix B: Therapeutic Alternatives*

*This table provides a listing of preferred alternative therapy recommended in the approval criteria. The drugs listed here may not be a formulary agent and may require prior authorization.*

Drug Name	Dosing Regimen	Dose Limit/ Maximum Dose
fenofibrate (TriCor <sup>®</sup> )	HyperTG without ASCVD: 48-145 mg PO QD	145 mg/day
gemfibrozil (Lopid <sup>®</sup> )	HyperTG without ASCVD: 600 mg PO BID	1,200 mg/day
omega-3-acid ethyl esters (Lovaza <sup>®</sup> )	HyperTG without ASCVD: 4 g PO QD or 2 g PO BID	4 g/day

*Therapeutic alternatives are listed as Brand name<sup>®</sup> (generic) when the drug is available by brand name only and generic (Brand name<sup>®</sup>) when the drug is available by both brand and generic.*

*Appendix C: Contraindications/Boxed Warnings*

- Contraindication(s): known hypersensitivity (e.g., anaphylactic reaction) to Vascepa or any of its components
- Boxed warning(s): none reported

*Appendix D: High and Moderate Intensity Daily Statin Therapy for Adults*

High Intensity Statin Therapy
<i>Daily dose shown to lower LDL-C, on average, by approximately ≥ 50%</i>
<ul style="list-style-type: none"> <li>• Atorvastatin 40-80 mg</li> <li>• Rosuvastatin 20-40 mg</li> </ul>
Moderate Intensity Statin Therapy
<i>Daily dose shown to lower LDL-C, on average, by approximately 30% to 50%</i>
<ul style="list-style-type: none"> <li>• Atorvastatin 10-20 mg</li> <li>• Fluvastatin XL 80 mg</li> <li>• Fluvastatin 40 mg BID</li> <li>• Lovastatin 40 mg</li> <li>• Pitavastatin 1-4 mg</li> <li>• Pravastatin 40-80 mg</li> <li>• Rosuvastatin 5-10 mg</li> <li>• Simvastatin 20-40 mg</li> </ul>

**Low Intensity Statin Therapy**

*Daily dose shown to lower LDL-C, on average, by < 30%*

- Simvastatin 10 mg
- Pravastatin 10-20 mg
- Lovastatin 20 mg
- Fluvastatin 20-40 mg

*Appendix E: Statin Risk Factors*

**Statin Risk Factors**

- Multiple or serious comorbidities, including impaired renal or hepatic function
- Unexplained alanine transaminase (ALT) elevations > 3 times upper limit of normal, or active liver disease
- Concomitant use of drugs adversely affecting statin metabolism
- Age > 75 years, or history of hemorrhagic stroke
- Asian ancestry

*Appendix F: Statin Contraindications*

**Statins**

- Decompensated liver disease (development of jaundice, ascites, variceal bleeding, encephalopathy)
- Laboratory-confirmed acute liver injury or rhabdomyolysis resulting from statin treatment
- Pregnancy\*, actively trying to become pregnant, or nursing
- Immune-mediated hypersensitivity to the HMG-CoA reductase inhibitor drug class (statins) as evidenced by an allergic reaction occurring with at least TWO different statins

*\*In July 2021, the FDA requested removal of the contraindication against use of statins in pregnant women. Because the benefits of statins may include prevention of serious or potentially fatal events in a small group of very high-risk pregnant patients, contraindicating these drugs in all pregnant women is not appropriate.*  
<https://www.fda.gov/safety/medical-product-safety-information/statins-drug-safety-communication-fda-requests-removal-strongest-warning-against-using-cholesterol>

*Appendix G: Risk Factors for CVD (2021 ADA and 2013 AHA Guidelines)*

- Men and women  $\geq 50$  years of age
- Cigarette smoker or stopped smoking within 3 months
- Hypertension (blood pressure  $\geq 140$  mmHg systolic OR  $\geq 90$  mmHg diastolic) or on antihypertensive medication
- HDL-C  $\leq 40$  mg/dL for men or  $\leq 50$  mg/dL for women
- Renal dysfunction: creatinine clearance (CrCL)  $> 30$  and  $< 60$  mL/min or chronic kidney disease
- Micro- or macroalbuminuria
  - Microalbuminuria: either a positive micral or other strip test (may be obtained from medical records), an albumin/creatinine ratio  $\geq 2.5$  mg/mmol, or an albumin excretion rate on timed collection  $\geq 20$  mg/min all on at least two successive occasions

- Macroalbuminuria: Albustix or other dipstick evidence of gross proteinuria, an albumin/creatinine ratio  $\geq 25$  mg/mmol, or an albumin excretion rate on timed collection  $\geq 200$  mg/min all on at least two successive occasions
- Obesity/overweight
- Dyslipidemia
- Family history of premature coronary disease

*Appendix H: General Information*

- The diagnosis of SAMS is often made based on clinical criteria. Typical SAMS include muscle pain and aching (myalgia), cramps, and weakness. Symptoms are usually bilateral and involve large muscle groups, including the thigh, buttock, back, and shoulder girdle musculature. In contrast, cramping is usually unilateral and may involve small muscles of the hands and feet. Symptoms may be more frequent in physically active patients. Symptoms often appear early after starting statin therapy or after an increase in dose and usually resolve or start to dissipate within weeks after cessation of therapy, although it may take several months for symptoms to resolve completely. Persistence of symptoms for more than 2 months after drug cessation should prompt a search for other causes or for underlying muscle disease possibly provoked by statin therapy. The reappearance of symptoms with statin rechallenge and their disappearance with drug cessation offers the best evidence that the symptoms are truly SAMS.
- Pravastatin, fluvastatin, and rosuvastatin are hydrophilic statins which have been reported to confer fewer adverse drug reactions than lipophilic statins.

**V. Dosage and Administration**

Indication	Dosing Regimen	Maximum Dose
Hypertriglyceridemia without ASCVD	2 g PO BID	4 g/day
Reduction of CVD risk		

**VI. Product Availability**

Capsules: 0.5 g, 1 g

**VII. References**

1. Vascepa Prescribing Information. Bedminster, NJ: Amarin Pharma, Inc.; December 2019. Available at: [www.vascepa.com](http://www.vascepa.com). Accessed September 30, 2021.
2. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2018;Nov 10:[Epub ahead of print].
3. Miller M, Stone NJ, Ballantyne C, et al. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2011; 123: 2292-2333.
4. Jellinger PS, Handelsman Y, Rosenblit PD, et al. American Association of Clinical Endocrinologists and American College of Endocrinology Guidelines for management of dyslipidemia and prevention of cardiovascular disease. Endocr Pract 2017;23(Suppl 2):1-87.
5. Berglund L, Brunzell JD, Goldberg AC, et al. Evaluation and treatment of hypertriglyceridemia: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2012;97(9):2969-2989.

6. Bhatt DL, Steg G, Miller M, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. *N Engl J Med*. 2019 Jan 1;380(1):11-22.
7. Skulas-Ray AC, Wilson PWF, Harris WS, et al. Omega-3 fatty acids for the management of hypertriglyceridemia: a science advisory from the American Heart Association. *Circulation*. 2019 Sep 17;140(12):e673-e691.
8. Manpuya WM, Cho L, Frid D, et al. Treatment strategies in patients with statin intolerance: the Cleveland Clinic experience. *American Heart Journal* 2013; 166(3):597-603.
9. Zhang H, Plutzky J, Skentzos S, et al. Discontinuation of statins in routine care settings. *Ann of Intern Med* 2013; 158(7):526-534.
10. Backes JM, Ruisinger JF, Gibson CA, et al. Statin-associated muscle symptoms—managing the highly intolerant. *J Clin Lipidol*. 2017;11:24-33. Available at: <https://www.acc.org/latest-in-cardiology/ten-points-to-remember/2017/05/03/10/43/statin-associated-muscle-symptoms>. Accessed September 30, 2021.
11. Thompson PD, Panza G, Zaleski A, et al. Statin-associated side effects. *JACC* 2016;67(20):2395-2410.
12. American Diabetes Association. 10. Cardiovascular disease and risk management: Standards of medical care in diabetes-2021. *Diabetes Care*. 2021;44(Suppl 1):S125-S150. Last updated June 16, 2021.
13. Goff DC Jr, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *Circulation*. 2014 Jun 24;129(25 Suppl 2):S49-73.
14. Virani SS, Morris PB, Agarwala A, et al. 2021 ACC expert consensus decision pathway on the management of ASCVD risk reduction in patients with persistent hypertriglyceridemia: a report of the American College of Cardiology Solution Set Oversight Committee. Endorsed by the National Lipid Association. *J Am Coll Cardiol*. 2021; 78(9): 960-993.
15. Kleindorfer DO, Towfighi A, Chaturvedi S, et al. 2021 guideline for the prevention of stroke in patients with stroke and transient ischemic attack: A guideline from the American Heart Association/American Stroke Association. *Stroke*. 2021; 52: e354-e467.

Reviews, Revisions, and Approvals	Date	P&T Approval Date
1Q 2019 Policy created.	11.20.18	02.19
1Q 2020 annual review: added HIM line of business; retire HIM.PA.29 policy; criteria added for new FDA indication: CVD risk reduction; added Appendices D, E, F, and G; references reviewed and updated.	12.05.19	02.20
1Q 2021 annual review: no significant changes; added redirection to generic icosapent ethyl for brand Vascepa requests; references to HIM.PHAR.21 revised to HIM.PA.154; references reviewed and updated.	11.02.20	02.21
1Q 2022 annual review: no significant changes; revised from medical justification to must use; references reviewed and updated.	09.30.21	02.22

**Important Reminder**

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.



**Note:**

**For Medicaid members**, when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.

©2019 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene<sup>®</sup> and Centene Corporation<sup>®</sup> are registered trademarks exclusively owned by Centene Corporation.